Sep 18, 2024
Medivir to present at the Pareto Securities Healthcare Conference
Sep 16, 2024
Medivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO
Sep 12, 2024
Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16
Aug 22, 2024
MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2024
Jul 18, 2024
Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September
Jun 28, 2024
Number of shares and votes in Medivir AB on 28 June 2024
Jun 19, 2024
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility
May 30, 2024
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024
May 07, 2024
Resolutions at the Annual General Meeting in Medivir on 7 May 2024
Apr 30, 2024
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
Apr 23, 2024
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue
Apr 15, 2024
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
Apr 09, 2024
Medivir to present at Investing in Oncology Forum on April 10
Apr 04, 2024
Medivir 2023 Annual Report published
Mar 06, 2024
Medivir to present at Swiss Nordic Bio in Zürich on March 7
Mar 04, 2024
Medivir to present at the Life Science Day in Gothenburg on March 6
Feb 26, 2024
Change in Medivir's nomination committee before the 2024 AGM
Feb 15, 2024
MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2023
Jan 26, 2024
Medivir announces the outcome of the directed share issue which was announced on 22 January 2024
Jan 24, 2024
Medivir to present at the Redeye Fight Cancer Day